Onemednet director Thomas Kosasa buys $1 million in shares

OneMedNet insider Thomas Kosasa bought 1,449,275 shares for ~$1.0M at $0.69/share (VWAP-based), matching InvestingPro’s fair value estimate; the stock is ~$0.62 currently, down 13% over the past week, and the company remains cash-burning and unprofitable over the last 12 months. Separately, OneMedNet announced $3M+ in new 2026 bookings, exceeding total 2025 bookings, and expects to recognize most of this revenue by end of Q3 2026. Net: insider support and booking momentum are offset by ongoing losses and declining share price.

Analysis

The insider purchase is more signal for balance-sheet support than for durable upside. At this size, $1mm can help anchor the tape near the purchase level, but it does not change the core question: whether the company can convert headline bookings into cash-revenue before dilution pressure reasserts itself. In microcaps like ONMD, the market usually discounts press-release “bookings” until there is a clean filing showing deferred revenue, gross margin, and operating cash burn improving together.

The bigger second-order issue is financing optics. If management can show that the new bookings are real and collectible, the stock may get a short-term rerating because vendors, customers, and potential financing counterparties often view booked backlog as a de-risking event. But if revenue recognition slips or working capital expands faster than collections, the same announcement becomes evidence that growth is asset-light on paper but cash-intensive in practice, which typically precedes another capital raise at a discount.

Over the next few days, the insider purchase may stabilize trading; over 1-3 months, the real catalyst is the next filing and whether Q3 revenue catches up to the booking claim. Over 6-18 months, the thesis hinges on whether ONMD can turn this into a repeatable sales process rather than one-off commitments. What would falsify the constructive view: cash burn accelerating, share count rising, or revenue recognized materially below the implied run-rate from the bookings announcement.

Key Decisions for Investors

• No immediate directional trade; treat ONMD as a watchlist name until the next filing confirms backlog conversion, gross margin, and cash runway. The signal is too small to underwrite a full position today.
• If taking risk, use a small starter long only on a close back above the insider purchase level (~$0.69) with volume confirmation; stop on a sustained break below ~$0.58, where the market is likely re-pricing dilution risk.
• Reduce exposure or short any relief rally if the next filing shows revenue lagging the bookings headline or operating cash burn widening; that would likely compress the equity back toward distressed financing multiples.
• Set an alert for the next quarterly report: if recognized revenue and deferred revenue both step up while cash burn moderates, ONMD can re-rate; if not, the booking announcement should be treated as non-investable marketing noise.